Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly, and i.v.

Background: Thrombolysis for acute ischemic stroke has remained controversial. The Canadian Alteplase for Stroke Effectiveness Study, a national prospective cohort study, was conducted to assess the ...

Please provide your email address to receive an email when new articles are posted on . At 90 days after minor nondisabling acute ischemic stroke, there was no difference in functional outcomes ...

A noninferiority trial comparing two doses of thrombolytic therapy with the tissue plasminogen activator (tPA) alteplase has failed to demonstrate that low-dose therapy is as effective as ...

Thrombolytic therapy with alteplase is widely used for symptomatic PVT, but evidence comparing it directly with tenecteplase ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...

Medical staff have increased the use of tPA or "clot busting therapy" for ischemic stroke by 13.5 times throughout University Hospitals system hospitals since implementing the System Stroke Program ...

Working with animal models, researchers now have demonstrated the potential of giving a drug in combination with tPA that might improve stroke outcomes and increase the window of opportunity for the ...

Around 15 years have now elapsed since thrombolysis was first shown to be effective for treating acute ischemic stroke, but therapeutic uptake has been modest. As outlined in this Review, research ...

(HealthDay News) — Endovascular therapy with mechanical thrombectomy in ischemic stroke is superior to standard treatment with tissue plasminogen activator (tPA) for preserving brain function, ...

Until recently, i.v. alteplase was only recommended for use within 3 hours of symptom onset of AIS. [2–4] However, the results of two large clinical trials published in 2008 clearly demonstrated the ...